B.Riley analyst Kalpit Patel reiterated a Buy rating and $8.00 price target on Journey Medical Corp. (NASDAQ: DERM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 10-Q Journey Medical Corp For: Jun 30August 13, 2024 6:02 AM Form 8-K Journey Medical Corp For: Aug 12August 12, 2024 4:09 PM Dermira (DERM) Misses Q2 EPS by 3c, reaffirms FY GuidanceAugust 12, 2024 4:05 PM Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 12, 2024 4:01 PM